ACTR-IIB Antibody (G-7): sc-376593

ACTR-IIB Antibody (G-7) is a mouse monoclonal IgG2b kappa light chain antibody that detects ACTR-IIB protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-ACTR-IIB antibody (G-7) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. ACTR-IIB (G-7) antibody targets a protein that plays a crucial role in the transforming growth factor β signaling pathway, which regulates various cellular processes such as proliferation, differentiation, and apoptosis. ACTR-IIB (G-7) monoclonal antibody recognizes a protein that interacts with type I receptors to form a heteromeric complex vital for signal transduction from ligands like activin, influencing gene expression and developmental processes. ACTR-IIB expression in the brain highlights its importance in neurodevelopment and neuroplasticity, making ACTR-IIB (G-7) antibody valuable for research in developmental biology and neurobiology. ACTR-IIB (G-7) monoclonal antibody enables research into various physiological and pathological conditions, including developmental disorders and diseases related to dysregulated signaling pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ACTR-IIB Antibody (G-7) References:

1. A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development.  |  Armes, NA., et al. 1999. J Biol Chem. 274: 7929-35. PMID: 10075688
2. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance.  |  Busquets, S., et al. 2012. J Cachexia Sarcopenia Muscle. 3: 37-43. PMID: 22450815
3. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.  |  Relizani, K., et al. 2014. Mol Ther. 22: 1423-1433. PMID: 24861054
4. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.  |  Bayarsaikhan, O., et al. 2017. J Nutr Sci Vitaminol (Tokyo). 63: 244-248. PMID: 28978871
5. Electrical impedance myography as a biomarker of myostatin inhibition with ActRIIB-mFc: a study in wild-type mice.  |  Nagy, JA., et al. 2018. Future Sci OA. 4: FSO308. PMID: 30057785
6. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.  |  Lautaoja, JH., et al. 2019. Am J Physiol Endocrinol Metab. 316: E852-E865. PMID: 30860875
7. BMP3 suppresses colon tumorigenesis via ActRIIB/SMAD2-dependent and TAK1/JNK signaling pathways.  |  Wen, J., et al. 2019. J Exp Clin Cancer Res. 38: 428. PMID: 31665064
8. Cloning and characterization of a human type II receptor for bone morphogenetic proteins.  |  Rosenzweig, BL., et al. 1995. Proc Natl Acad Sci U S A. 92: 7632-6. PMID: 7644468
9. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin.  |  Cárcamo, J., et al. 1994. Mol Cell Biol. 14: 3810-21. PMID: 8196624
10. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.  |  Attisano, L., et al. 1993. Cell. 75: 671-80. PMID: 8242742
11. The ALK-2 and ALK-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not co-operate to establish thresholds.  |  Armes, NA. and Smith, JC. 1997. Development. 124: 3797-804. PMID: 9367435
12. Bone morphogenetic proteins and their receptors: potential functions in the brain.  |  Ebendal, T., et al. 1998. J Neurosci Res. 51: 139-46. PMID: 9469567

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ACTR-IIB Antibody (G-7) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-ACTR-IIB Antibody (G-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ACTR-IIB Antibody (G-7) Specifications

Alternate Product Name: ACVR2B

Product Clone Name: G-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 108-177

Epitope Target: ACTR-IIB

Epitope Species: human

Product Reactivity/Detection: ACTR-IIB

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for ACTR-IIB Antibody (G-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin